Ditch News
From us to you, our latest news.
Ditch Labs Receives Funding From The National Research Council's IRAP Program
Following the partnership between Ditch Labs, Inc. and the CRIM along with professional recommendations, the company’s application for the non-dilutive funding of the National Research Council’s IRAP program is now approved.
MONTREAL, QC/December, 2021 – Following the partnership between Ditch Labs, Inc. and the CRIM along with professional recommendations, the company’s application for the non-dilutive funding of the National Research Council’s IRAP program is now approved. These additional funds will finance the fees of the CRIM researchers.
Ditch Partners Up With The Computer Research Institute of Montréal (CRIM) To Develop Its Treatment Algorithms
The partnership of Ditch Labs, Inc. with the CRIM to develop its treatment algorithms led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Software Director Étienne Bélanger and Researcher Gabrielle Toupin, will strengthen the cybersecurity of its solutions.
MONTREAL, QC/December, 2021 – The partnership of Ditch Labs, Inc. with the CRIM to develop its treatment algorithms led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Software Director Étienne Bélanger and Researcher Gabrielle Toupin, will strengthen the cybersecurity of its solutions and allow the company to develop algorithms based on the data it collects from the DitchPen™ and from the DitchApp™, among other important aspects.
Ditch Opens Up New Headquarters In Montreal
Ditch Labs, Inc. opens up new headquarters located on Prince Arthur Street in Montreal following a virtual staff growth from 3 to 15 employees during the pandemic.
MONTREAL, QC/September, 2021 – Ditch Labs, Inc. opens up new headquarters located on Prince Arthur Street in Montreal following a virtual staff growth from 3 to 15 employees during the pandemic. The offices will include electronic, server and computational laboratories to serve all research and hardware initiatives. This new location will allow proximity to all downtown activities along with more accessibility for staff and team collaborators.
Ditch Joins The CTS Incubator, The Growth Accelerator For Healthcare Technology
Ditch Labs, Inc. officially joins the CTS incubator specialized in innovative healthcare technology and digital health solutions to secure initial financing to launch commercialization.
MONTREAL, QC/June, 2021 – Ditch Labs, Inc. officially joins the CTS incubator specialized in innovative healthcare technology and digital health solutions to secure initial financing to launch commercialization. This collaboration enables the introduction to strategic partners and investors, as well as access to high-quality mentorship and non-dilutive funding opportunities.
Smoking Cessation Startup Ditch Labs Completes $1.3 Million Pre-Seed Round to Solve Nicotine Addiction and Tobacco Use
Ditch Labs, a Montreal-based precision medicine company, is developing a new smoking cessation system and just completed a $ 1.3 million round of funding.
MONTREAL, June 17, 2021 — Ditch Labs, a Montreal-based precision medicine company, is developing a new smoking cessation system and just completed a $1.3 million round of funding.
The Montreal-based startup closed a pre-seed round in May 2021 with the participation of Amplify Capital, Desjardins Capital, Boreal Ventures, Anges Québec, Formentera Capital, the Healthcare innovation arm of Symphony Care Network, along with renowned tech entrepreneurs such as Cherif Habib (CEO of Dialogue) and Simon de Beane (CEO of GSoft), among others.
Addressing a huge unmet need
Smoking is still to this day the leading cause of preventable death with 1 out of every 5 deaths directly related to tobacco use. Even though over two thirds of smokers want to quit according to the Centers for Disease Control and Prevention, the average quit success rate has been hovering around 7% without showing any sign of improvement.
The Ditch solution
Founded by Laurent Laferrière and Olivier Bourbonnais, two serial entrepreneurs, Ditch Labs offers a revolutionary smoking cessation solution by developing the DitchPen™, a patent-pending medical vaporizer that precisely doses the quantity of nicotine administered, in order to reduce it automatically in a gradual and personalized way. The medical device is paired with a mobile application that uses machine learning algorithms to learn, adapt and act as a behavioural assistant throughout the withdrawal process.
The capital injection will allow the company to pursue preclinical studies, advance its global regulatory plan and further product and algorithm development. The company plans to market a first version of the DitchPen™ in the UK in 2022 and in Canada in 2024, following a rigorous regulatory process to approve the DitchPen™ as an aid to smoking cessation.